Skip to content

    Cell Therapy Clinical Trials

    Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

    Learn more

    What is the purpose of this study?

    The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies. A secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries. Objectives: To learn more about what makes stem cell transplants and cellular therapies work well such as: * Determine how well recipients recover from their transplants or cellular therapy; * Determine how recovery after a transplant or cellular therapy can be improved; * Determine how a donor's or recipient's genetics impact recipient recovery after a transplant or cellular therapy; * Determine how access to transplant or cellular therapy for different groups of patients can be improved; * Determine how well donors recover from the collection procedures.

    Eligibility

    Eligibility to Participate in the Research Database

    Recipient Eligibility Criteria:

    • Any recipient of an unrelated or related donor or autologous HSC transplant in a CIBMTR center is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children.

    Individual with Marrow Toxic Injury Eligibility Criteria:

    • Any individual who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Transplant Network (RITN) is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Eligible individuals may have received supportive care only, growth factor support, HSC transplant or other appropriate medical treatment for marrow toxic injury. Treatments applied are at the discretion of the care facility, and are not determined by the NMDP or CIBMTR.

    Unrelated Donor Eligibility Criteria:

    • All donors registered on the NMDP Registry who have been requested to donate a product for a recipient are eligible to participate in the Research Database.
    • All maternal cord blood donors are enrolled in the NMDP Cord Blood Bank Investigational New Drug (IND) protocol, and sign an informed consent document specific to that protocol. Data collected as part of the Cord Blood Bank protocol are included in the Research Database.

    Where can I participate?

    Hoag Hospital Newport Beach
    1 Hoag Dr
    Newport Beach, CA 92663


    Lauren Wagner

    lauren.wagner@hoag.org


    Hoag Hospital Irvine
    16200 Sand Canyon Ave
    Irvine, CA 92618


    Lauren Wagner

    lauren.wagner@hoag.org


    More about this Clinical Trial

    What is the full name of this Clinical Trial?

    Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

    • Disease Type/ConditionAutologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Solid Tumors, Blood Cancers, CAR-T, Gene Therapy, Non-malignant Disease
    • Principal InvestigatorBenjamin H. Goldenson. MD
    • Co-InvestigatorsRaghuveer Ranganathan, MD, Eduardo Fernanadez Hernandez
    • Age GroupChild, Adult, Older Adult
    • ClinicalTrials.gov IDNCT01166009

    Hoag Family Cancer Institute

    Hoag Family Cancer Institute delivers advanced, compassionate cancer care across Orange County, with multidisciplinary specialists, precision therapies, support services, and access to 125+ cancer clinical trials. Patients benefit from research-driven care across a wide range of cancers, including breast, lung, gynecologic, prostate, gastrointestinal, and blood cancers.

    Learn More
    Dr. Grossman in a white coat writing on a board

    Stay up-to-date on the latest news from Hoag

    By submitting this request, you agree to receive communications from Hoag and accept our Privacy Policy and Terms of Use.